Alterations of glycaemia, insulin resistance and body mass index within the C-peptide optimal range in non-diabetic patients

Kron, Vladimír; Verner, Miroslav; Smetana, Pavel; Janoutová, Jana; Janout, Vladimí­r; Martiník, Karel

doi:10.32725/jab.2020.018

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Корреляционная связь между содержанием С-пептида и кардиометаболическими показателями у женщин 25-44 лет 2 В настоящем исследовании осуществлен перевод показателей ТГ из мг/дл в ммоль/л по формуле: ТГ (ммоль/л) = ТГ (мг/дл) / 88,5 [18]. 3 В настоящем исследовании осуществлен перевод показателей креатинина из мг/дл в мкмоль/л по формуле: креатинин (мкмоль/л) = креатинин (мг/дл) × × 88,4 [17]. 4 В настоящем исследовании осуществлен перевод показателей ГПН из мг/дл в мммоль/л по формуле: ГПН (ммоль/л) = ГПН (мг/дл) / 18,02 [18].…”

Section: показатель / Parametersunclassified

“…чении ИМТ по мере повышения содержания С-пептида. Так, V. Kron et al заявили, что в выборке из 3186 человек в возрасте от 15 до 78 лет ИМТ увеличился с 28,3 ± 5,2 кг/м 2 в 1-м квартиле С-пептида до 37,4 0± 6,3 кг/м 2 в 4-м квартиле, р < 0,001 [17]. В сочетании с представленными выше данными о более низком уровне С-пептида у лиц с МЗФ по сравнению с МНЗФ полученные нами результаты выглядят закономерно.…”

Section: показатель / Parametersunclassified

See 1 more Smart Citation

Associations of C-peptide with cardiometabolic parameters in women aged 25–44 years with different metabolic phenotypes

Мустафина

Alferova

Щербакова

et al. 2023

jour

View full text Add to dashboard Cite

The development of atherosclerotic diseases is pathogenetically associated with an increase in insulin resistance, an indirect marker of which is the C-peptide. In addition, literature data indicate the intrinsic proatherogenic effects of C-peptide. In recent years, the concept of separating metabolically healthy (MHP) and unhealthy phenotype (MUHP) at different body weights has become increasingly widespread. It believed that the key difference between MHP and MUHP is the more pronounced insulin resistance in the latter, but there are no clear data on the association of C-peptide with MHP or MUHP. Aim of the study was to investigate the association of C-peptide level with different metabolic phenotypes in women aged 25–44 years. Material and methods. The study was conducted on the basis of a representative sample of women aged 25–44 years (n = 1513, of which 840 women). The analysis included indicators of 655 women. The definition of MHP and MUHP carried out using the IDF criteria, 2005 for the diagnosis of metabolic syndrome. Anthropometric measurements, biochemical and hormonal blood tests have been carried out in groups divided by the body mass index (BMI). The level of C-peptide was determined by the method of multiplex analysis. Results. C-peptide content in the examined sample was 0.9 [0.5; 1.3] ng/ml (Me [Q1; Q3]), with MHP – 0.8 [0.5; 1.1] ng/ml, with MUHP – 1.3 [0.7; 1.8] ng/ml, p < 0.0001. With an increase in BMI, the median of C-peptide increased both in MHP (from 0.8 [0.4; 1.1] to 1.2 [0.8; 1.7] ng/mL, ptrend < 0.0001) and with MUHP (from 0.8 [0.2; 1.2] to 1.5 [0.9; 2.1] ng/mL, ptrend = 0.006). The frequency of MUHP in the 4th quartile of the C-peptide is 2.7 times higher than in the 1st quartile (p < 0.0001), and the frequency of MHP – 1.6 times lower (p = 0.001). C-peptide content correlated with anthropometric parameters, glucose, lipid concentration, transaminase activity, kidney filtration capacity. A C-peptide level of more than 1.33 in young women indicates a high probability of having MUHP with maximum sensitivity and specificity (Se = 49.3 %, Sp = 85.9 %). Conclusions. In women with MUHP, C-peptide content is 38.5 % higher than in women with MHP. The frequency of MUHP in the 4th quartile of the C-peptide is 3.2 times higher than in the 1st quartile. The level of C-peptide above 1.33 ng/ml is associated with the presence of MUHP.

show abstract

Section: показатель / Parametersunclassified

Associations of C-peptide with cardiometabolic parameters in women aged 25–44 years with different metabolic phenotypes

Мустафина

Alferova

Щербакова

et al. 2023

jour

View full text Add to dashboard Cite

show abstract

C-Peptide and BMi predict anti-hyperglycemic treatment lines in breast cancer patients treated with Alpelisib

Carrillo-Lopez,

Sebastian-Valles,

Sager La Ganga

et al. 2024

Endocrine

View full text Add to dashboard Cite

Purpose Alpelisib is a PI3K (Phosphoinositide 3-kinases) inhibitor used for breast cancer which develops hyperglycemia based on its action on glucose metabolism regulation. This study aims to identify potential risk factors predicting hyperglycemia development and the need for multiple treatments for hyperglycemia in patients receiving Alpelisib. Methods Fourteen women diagnosed with metastatic hormone receptor-positive breast cancer carrying PI3K mutations who initiated treatment with Alpelisib were monitored through consultations in the Oncology and Endocrinology departments. Non-parametric ROC curves were generated to assess the need for three or more antidiabetic medications to achieve glycemic control. Results The study population had a median age of 64 years (range:48–69) with a median body mass index (BMI) of 26.6 kg/m2 (range: 22.9–29.4). Overweight was observed in 35.7% of the participants and obesity in 21.4%. Fifty percent of the participants had prediabetes, and 85.7% developed hyperglycemia requiring pharmacological treatment, although none of them needed to discontinue treatment for this reason. Baseline C-peptide levels and BMI were associated with the number of antidiabetic drugs used (Spearman’s Rho 0.553, p = 0.040; Spearman’s Rho 0.581, p = 0.030, respectively). ROC curve analysis showed and area under the curve (AUC) of 0.819 for the variable risk profile (defined as baseline C-peptide >10.5 ng/ml and BMI > 27 kg/m2), whereas AUC values were 0.556 and 0.514 for HbA1c and baseline glucose, respectively, (p = 0.012). Conclusion A joint follow-up by an Oncology department and a Diabetes Unit can prevent treatment discontinuation in patients under Alpelisib therapy. Baseline BMI and plasma C-peptide levels can predict an increased need for anti-hyperglycemic treatment.

show abstract

Alterations of glycaemia, insulin resistance and body mass index within the C-peptide optimal range in non-diabetic patients

Cited by 2 publications

References 21 publications

Associations of C-peptide with cardiometabolic parameters in women aged 25–44 years with different metabolic phenotypes

Associations of C-peptide with cardiometabolic parameters in women aged 25–44 years with different metabolic phenotypes

C-Peptide and BMi predict anti-hyperglycemic treatment lines in breast cancer patients treated with Alpelisib

Contact Info

Product

Resources

About